ADTX · As filed with the SEC
Aditxt income statement, by fiscal year
The statement as Aditxt presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 |
|---|---|---|
| REVENUE | ||
| Sales | 3,195 | 133,985 |
| Cost of goods sold | 2,927 | 627,474 |
| Gross profit (loss) | 268 | (493,489) |
| OPERATING EXPENSES | ||
| General and administrative expenses $0 and $33,071in stock-based compensation, respectively | 15,974,863 | 16,286,216 |
| Research and development $10,000 and $6,712,663 in stock-based compensation, respectively | 3,194,133 | 10,886,130 |
| Sales and marketing $473,311 and $0 in stock-based compensation, respectively | 401,996 | 197,863 |
| Total operating expenses | 19,570,992 | 27,370,209 |
| NET LOSS FROM OPERATIONS | (19,570,724) | (27,863,698) |
| OTHER INCOME (EXPENSE) | ||
| Interest expense | (681,156) | (4,188,725) |
| Interest income | 200,179 | 1,454 |
| Amortization of debt discount | (1,706,697) | (3,174,920) |
| Gain (loss) on note exchange agreement | — | (208,670) |
| Change in fair value of derivative liability | 14,515 | 414,501 |
| Change in fair value of Evofem warrants | 2,806,983 | — |
| Impairment of Evofem F-1 Preferred Stock | (23,766,209) | — |
| Bargain purchase gain from purchase of Evofem convertible notes | 328,071 | — |
| Impairment of fixed assets | (412,005) | — |
| Total other expense | (23,216,319) | (7,156,360) |
| Net loss before income taxes | (42,787,043) | (35,020,058) |
| NET LOSS | (42,787,043) | (35,020,058) |
| Deemed Dividends | (1,387,250) | (5,907,011) |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | (1,072,842) | (573,572) |
| NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES | (43,101,451) | (40,353,497) |
| Net loss per share, basic (in Dollars per share) | (1,153.83) | (22,147,415.22) |
| Net loss per share, diluted (in Dollars per share) | (1,153.83) | (22,147,415.22) |
| Weighted average number of shares outstanding during the period, basic (in Shares) | 37,355 | 2 |
| Weighted average number of shares outstanding during the period, diluted (in Shares) | 37,355 | 2 |
| COMPREHENSIVE LOSS: | ||
| Net Loss | (42,787,043) | (35,020,058) |
| Other Comprehensive Loss: | ||
| Change in valuation of Evofem note | 1,254,170 | — |
| TOTAL COMPREHENSIVE LOSS | (41,532,873) | (35,020,058) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.